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Summary Interstitial photodynamic therapy has a number of potential advantages over superficial treatment.
We have treated 50 subcutaneous and cutaneous tumours interstitially, in nine patients. An additional 22
tumours in the same patients, were treated by superficial PDT. Patients received 1.5 -2.0 mg kg of
polyhaematoporphyrin and 72 h later underwent treatment using a copper vapour dye laser producing red
light at 630 nm.
All interstitial treatments were delivered using cylindrical diffusing fibres and a wide range of light doses
(5-1500 J cm-3). The complete response rate for all tumours treated interstitially was 52%, rising to 81% in
those patients who received 2.0 mg kg-' PHP and light doses in excess of 500 J cm-3. The overall incidence of
skin necrosis was 32% and was 79% in those treated with light doses of greater than 500 Jcm-3. The
incidence of skin necrosis with interstitial PDT is lower than that seen with superficial photodynamic therapy
but higher volumetric light doses are required to produce tumour complete responses. All treatments were well
tolerated and volumes of tumour up to 60 cm3 were successfully treated. The penetration depth of 630 nm light
in human breast cancer tissue was determined as 4 mm. Little true tumour tissue selectivity was detected by
analysis of porphyrin levels in biopsy material.
Photodynamic therapy (PDT) generally involves the systemic
administration of a photosensitiser that is retained with some
selectivity in tumour tissue when compared with the normal
tissue from which the tumour arose (Gomer et al., 1979;
Tralau et al., 1987). The drug is then photoactivated by light
of the appropriate wavelength and this leads to localised
tumour necrosis which is primarily consequent to vascular
collapse (Henderson et al., 1985; Star et al., 1986). It can be
applied safely after other modalities of treatment such as
radiation or chemotherapy (Dougherty, 1984; Gilson et al.,
1988). The results of clinical studies demonstrate that
superficial therapy can be very effective for small superficial
tumours (Dougherty, 1984; Gilson et al., 1988; Kato et al.,
1986; Parrish, 1983; Robinson et al., 1988; Unsold et al.,
1990) and that interstitial therapy shows promise for the
treatment of small tumours, but should also allow treatment
of non-superficial tumours (Barr et al., 1990; Monnier et al.,
1990).
One of the major disadvantages of current PDT, especially
of relevance to superficial treatment, relates to the poor
penetration of red light at 630 nm. Previous studies have
shown that the optical penetration depth (l/e or 37% level)
in tumours, ranges from 1-3 mm (Svaasand, 1984),
2.7-4.5 mm (Wilson, 1986) and more recently in vivo
measurements in human breast tumours 2.9-4.7 (Driver et
al., 1991). Photoactivation can occur at greater depths than
this and effective penetration of up to 1 cm can be achieved
(Dougherty, 1984; Gilson et al., 1988). Newer drugs activated
at longer wavelengths offer the potential to improve the
penetration depths by a few millimetres, but are not likely to
extend it much beyond this.
Interstitial therapy, using multiple fibres, should enable
tumours of much larger volumes to be effectively treated and
by delivering the light to the point of interest, limit the
volume of normal tissue irradiated. Also, by reducing the
incident light dose to the skin surface, it should decrease the
incidence of skin necrosis, which is a feature of superficial
therapy. In animal tumour systems interstitial PDT has been
shown to be superior to superficial PDT (Marijnissen et al.,
1989). We have previously shown that plane cut fibres are
unsatisfactory for interstitial PDT (Gilson et al., 1988),
because of thermal effects (Feather et al., 1990) at the fibre
tip and that diffusing fibres are the fibres of choice for
interstitial PDT.
The aims of this study were to investigate interstitial PDT
using cylindrical diffusing fibres. To identify response criteria
in respect of light and drug doses for tumour and normal
tissue effects, determine the volume of tumour that could be
successfully treated interstitially and to compare interstitial
treatment with superficial therapy in relation to its efficacy
and examine the equivalence of light dose from these two
methods of light delivery.
Patients and methods
Between November 1988 and January 1990 nine patients
aged 46-79 (mean 66) were treated, two of whom were
re-treated, photodynamic therapy. All had received prior
treatment with radiotherapy and often chemotherapy. Five
had adenocarcinomas of the breast, three squamous car-
cinoma of the lung and one squamous carcinoma of the
pinna. All had either cutaneous or subcutaneous metastases
or a mixture of both. Fifty tumours were treated using purely
interstitial techniques with cylindrical diffusing fibres. Twenty
additional tumours in these same patients were treated by
superficial photodynamic therapy and the response data
accumulated were used to compare light dose equivalence
with matched tumours treated by interstitial PDT. All
tumours were carefully measured in three dimensions using
vernier calipers and allowed tumour volumes to be cal-
culated.
Patients were all treated as in-patients. All gave informed
consent and received either 1.5 mg kg-i or 2.0 mg kg-1
polyhaematoporphyrin (PHP) intravenously. PHP is a
material apparently identical to Photofrin II in chemical and
biological tests and is produced in our laboratories. Seventy-
two hours later the tumours were irradiated with 630 nm
light from a copper vapour dye laser. Patients were carefully
counselled with respect to permissable levels of exposure to
light.
Ten tumour and four skin biopsies were performed and
assayed for porphyrin levels with corresponding serum sam-
ples by the Department of Biochemistry, University of Leeds,
using spectrofluorimetry.
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All interstitial treatments were carried out using strict
asepsis and appropriate anaesthetic techniques. Prior to the
insertion of treatment fibres, the skin was anaesthetised with
1% or 2% lignocaine. Two hundredgLm diffusing fibres were
positioned for treatments using 19 G needles. When more
than one fibre was needed to obtain uniform irradiation of
the tumour, parallelism was ensured by means of templates,
and when more than one plane was required, fibres were
afterloaded into 1.6 mm plastic tubes, which had been posi-
tioned using techniques derived from brachytherapy and
usually under a general anaesthetic.
Isotropic detector fibres were placed on the skin overlying
the tumour, within the tumour itself, or at the interface of
the tumour and 'normal' tissue, during treatment, in order to
enable comparisons of responses with delivered light dose
and to allow measurements of in vivo optical interaction
coefficients.
The cylindrical diffusing fibres were manufactured indivi-
dually (Feather et al., 1989), and were calibrated to the
appropriate power density for treatment using an integrating
sphere prior to insertion in the tumour. Dose was specified in
J cm-2 for superficial PDT and is usually quoted as J cm '
for interstitial treatment. The light from superficial PDT is
not all absorbed within the tissues because of scatter without
absorption. Interstitial treatment should result in almost all
the light being absorbed and by equating the dose to the
tumour volume in which it is delivered, a dose in J cm3 is
derived. The output powers per unit length of diffuser were
between 70-300 mW cm' but wherever possible these were
kept below 150 mW cm` to minimise the possibility of pro-
ducing significant hyperthermia (temperatures above 41 C)
(Feather et al., 1990).
Forty-three tumours with volumes of 0.1-1.9cm 3 were
treated with a single diffusing fibre oflength 0.5-2.0 cm and
a range of light doses from 5 Jcm-3, to in excess of
1500 Jcm-3; four tumours with volumes of 2.3-4.9 cm-3
were treated with two fibres oflength 1.0-2.5 cm using light doses of 85-170Jcm-3. Three tumours were treated with
multiple fibres (6-8 fibres with a fibre separation of
8-12 mm, placed in two planes) and diffusers of lengths 1.5-6 cm, to treat volumes of 18.7-60cm-3, with light doses
of 75-200 Jcm-3. These fibre separations were based on
both an existing knowledge of the tissue penetration depth, and from known measurements of the depth of treatment
induced necrosis in an animal model. The range of light doses chosen in the single fibre group, reflect the fact that
this was an exploratory study and the range quoted is appar- ently larger than was clinically the case because the doses are
calculated volumetrically.
Light doses of 25-75 J cm-2 were used for superficial
treatment and tumours were treated with a margin of 1cm.
The dose rate at the skin surface were kept below
l50mWcm-2. Direct comparisons were attempted between
superficial and interstitially delivered treatments with respect
to treatment outcome, normal tissue damage and an estimate
of the equivalence of light doses to produce a complete
response in tumours treated. Comparisons were only made
with closely matched cutaneous or subcutaneous tumours of
similar dimensions. For superficial treatment the dose in
J cm-2 is multiplied by the area treated and expressed as a
dose delivered to the tumour minus 50% reflectance and
divided by the volume in which the light is delivered. This
50% figure represents light reflected at the tissue/air interface
and light scattered out from the tissues (Parrish, 1983). It is
also assumed that the light is effectively absorbed within a
depth of 0.5-0.7 cm. A dose in Jcm-3 isthus derived which
can then be compared with light delivered interstitially. Patients were reviewed weekly for a month then two
weekly. Clinical responses were judged at two months from
treatment and a complete response documented when the
treated lesion was impalpable, or response documented ac-
cording to the WHO criteria. Normal tissue responses were
recorded with particular attention to the incidence of skin
necrosis or eschar formation.
Results
Treatments were well tolerated with no clinically significant
photosensitivity. All areas of skin necrosis have healed and
normal tissue healing occured without obvious scar forma-
tion within 2-3 months. Tumour responses were commonly
rapid and evident within the first week. Figure 1 illustrates
the placement techniques used for treatment of the largest
tumour and sequential healing of a large area of necrosis
consequent to complete tumour lysis.
Plasma porphyrin levels on treatment day (72 h) were
1.8 ytg ml-' ± 0.7 for patients who received 1.5 mgkg-' PHP
and 3.4pg ml- ± 1.1 in those receiving 2.0mgkg'-. Results
of porphyrin analysis in plasma and biopsy material are
shown in Table I. Although the numbers ofthese biopsies are
small the tumour: normal tissue (skin) ratios are 1.1:1.0 and
therefore do not show much tumour selectivity.
Light and drug dose responses
The complete response rate for 50 tumours treated inter-
stitially was 26/50 = 52% (Table II). A 10% response at
1.Smgkg- PHP, 63% at 2.Omgkg-' and 81% in those
treated at the highest light and drug doses. The overall
incidence of eschar formation was 32% (16/50), 38% at
2.0mgkg-' PHP and 63% in those treated at the highest
light and drug doses (Table III) and was 62% when ex-
pressed as a percentage of lesions producing a complete
response. No eschars were seen in lesions that did not pro-
duce a complete response. No lesion that produced a com-
plete response was seen to recur at the treated site during the
period of follow up in any patient. Table IV examines the
results of single nodules treated with one fibre in order to
ascertain a volume that can be successfully treated using a
single fibre. A higher response was seen at doses greater than
100J cm-3 for tumours less than 1.0cm3: 18/31 (58%),
compared to those treated with light doses of less than
lOOJ cm-3 or tumours with volumes greater than 1.0 cm3:
4/12 (33%). It should be stressed, however, that using multi-
ple fibres, in excess of 60 cm-3 of tumour have been success-
fully treated. Figure 2 shows the relationship between tumour
volume and total delivered light dose in joules.
Comparisons between superficial and interstitial PDT
Table V examines the doses of light required to achieve
complete responses in tumours of comparable dimensions
treated by either superficial or interstitial PDT. It is ex-
tremely difficult to obtain such information clinically and
although these data were obtained from a larger light dose
response study it is not implicit that the quoted doses repre-
sent the threshold for complete response. Had lower light
doses been delivered to individual tumours the same tumour
response may have ensued. It is appreciated that this attempt
to compare the equivalence oflight doses can only be verified
by in vivo measurements both within the tumour and at
normal tissue/tumour boundaries; These measurements can
complicate an otherwise simple treatment, are usually
invasive, and by increasing local haemorrhage may interfere
with the therapeutic outcome, and hence they may have been
counterproductive in such a dose exploratory study.
In vivo light dosimetry
In six tumours, a short calibrated detector fibre was placed at
the base of the tumour throughout the duration of treatment.
In these cases the tumours were spherical and measured
approximately 0.5 cm-2. The energy fluence rate measured at
this point should equate to that received at the skin surface,
as the treatment fibre was equidistant from the skin and the
detector fibre. Although at the base of the tumour some of
the signal is due to backscattered light from below whereas at
the skin some light is lost. A biopsy of an untreated nodule
was used to provide a best estimate of photosensitiser con-
centration in the irradiated lesion. Ideally one would like to1400 C.P. LOWDELL et al.
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Figure 1 A large fixed axillary recurrence measuring 5.4 x 4 x 2.8 cm a, The patient had previously had radical radiotherapy and
had received surgery, hormonal therapy and chemotherapy, as treatment for this recurrence. PDT treatment was delivered using a
maximum length of 6 cm cylindrical diffuser. These were placed in plastic tubes which had been implanted into the tumour in two
planes, with a 12 mm separation both between the tubes and between planes (see Materials and methods section). Each channel
was treated separately b, A mean integral light dose of 43.7 J cm-2 was measured in two separate measuring channels which were
sited equidistantly between four tubes within the substance of the tumour. The patient received 2 mgkg-' PHP. Complete healing
of the resulting ulceration c, occurred within 3 months d. The nodule seen inferior to the main mass measured 2.3 cm3 and was
treated with two 1 cm diffusers with 0.8 cm separation between fibres to a dose of 171 J cm-3.INTERSTITIAL PDT OF SUPERFICIAL TUMOURS 1401
Table I Poryphyrin analyses at treatment time (72 h)
Dose of PHP Skin Serum Tumour
mgkg-' ng mg-' tg ml-' ng mg' Response
1.5 1.54 2.27 2.07 NC
1.5 2.86 4.79 CR/PR
2.0 0.92 2.0 1.43 NC
2.0 4.76 2.56 PR
2.0 3.23 1.48 NC
2.68 3.4 PR
2.0 3.85 2.83 2.52 NC
2.0 2.88 3.23 1.96 CR
2.0 41.20a 10.87a
4.18 2.23 PR
Plasma (jAg ml'), tumour (ng mg-) and skin levels (ng mg-') and
treatment result in terms of CR/PR/R/NC. Where CR = Complete
Responder; PR = Partial Responder; NC = No Change; PHP given
intravenously at 1.5 or 2.0 mg kg-'. [NB: ig ml-' = ngmg']. aI h
post PHP.
Table II Interstitial PDT using diffusing fibres
Light dose Drug dose mgkg-'
Jcm-3 1.5 2.0
<50 0/1 0/2
50-99 0/1 3/4
100-499 0/3 9/18
>500 1/5 13/16 (81%)
10% 63%
Overall CR 26/50 = 52%. Fifty tumours, nine patients, two of
whom were retreated. Complete response rate expressed as a fraction
of total number treated.
Table III Interstitial PDT using diffusing fibres
Light dose Drug dose mgkg-'
Jcm-3 1.5 2.0
< 50 0/1 0/2
50-99 0/1 1/4
100-499 0/3 4/18
> 500 1/5 10/16 (63%)
Overall 16/50 = 32%. Incidence of skin necrosis or eschar
formation expressed as a fraction of the total number of tumours
treated.
Table IV Interstitial PDT using diffusing fibres
Light dose Volume cm?
Jcm-3 0-0.5 0.5-1.0 1-2 >2
<50 (0%) 0/2 0/1
50-99 (33%) 1/2 0/1
100-499 (44%) 1/5 5/8 1/2 0/1
> 500 (67%) 10/16 2/2 2/3
All treatments were with single fibres and to single nodules.
Complete responses expressed in terms of light dose and tumour
volume. A 1 cm x I cm x 1 cm nodule = 0.52cm3. (Percentages in
parentheses are for all tumours treated at these light doses).
be able to monitor tumour drug concentration during treat-
ment and to continuously measure light fluence to derive a
photodynamic dose. In clinical practice this is not yet possi-
ble. Table VI illustrates the results obtained from such
measurements.
When multiple fibre, volume, treatments were carried out,
a separate measurement channel enabled an integrated energy
fluence to be ascertained. In these cases, a mean integral dose
(derived from two measuring channels) of 44 J cm-2, with a
plasma porphyrin level at treatment time of 4.21 tgmlh-,
produced a complete response in one patient (Drug x
Light = 185.24 - ratio of plasma:tumour not corrected). The
product of light and drug should allow reciprocal com-
parisons to be made between the relative contributions of
light and drug doses. 57.0Jcm2 with a plasma porphyrin
1.061gml-', produced a partial response in another patient
(Drug x Light = 60.4), although this patient apparently had
a very high tumour porphyrin level (14.15 ngmgi). How-
ever, a light dose of 132.9 J cm-2 with a plasma porphyrin of
2.0jigml-' (Drug x Light = 265.8), in the third patient, pro-
duced no change in the overall dimensions of the tumour but
3 x 1 cm of necrosis on CT measurements. These are
amongst the first such attempts to derive true photodynamic
dose in terms of the product of porphyrin dose and light
fluence and the discrepancies are indicative of the difficulties
involved in the accurate determination of such data.
Discussion
These data, although limited, do not provide much evidence
of true tumour specificity in terms of drug localisation. Our
analysis represents a total porphyrin concentration and does
not determine anything about the distribution of porphyrin
within the tumour. Achieving selective tumour destruction
must therefore depend on differential normal tissue healing,
differential distribution of light between tumour and normal
tissue and differential photodegradation.
Healing of skin eschars and areas of ulceration, even when
extensive, were remarkable supporting the different
mechanisms of tissue injury related to PDT in distinction to
thermal, Nd:YAG laser (Castro et al., 1983; Barr et al.,
1987) or radiation damage. This difference would appear to
be a consequence of the preservation of subcutaneous col-
lagen allowing healing to occur by regeneration rather than
by scarring, and remains one of the most advantageous
aspects of clinical PDT treatments (Barr et al., 1987).
Although tumour destruction is a function of the
porphyrin/light product it has not been our experience, that
lower drug dose and higher light doses, or the converse, can
achieve as satisfactory complete response rates as higher drug
and light doses. Reciprocity of drug and light dose has been
shown in experimental animal systems except when drug
doses were reduced below a threshold value (Fingar &
Henderson., 1987; Cowled & Forbes., 1985).
Previous measurements of the energy fluence at the eschar
edge in patients undergoing superficial therapy showed a
mean of 86 ± 31 J cm-2 (16 Observations) (Driver, 1990).
The interstitial results from Patient PT suggest a threshold
for both eschar formation and tumour response between
75 J cm-2 and 101 J cm-2. However the patient NL res-
ponded to lower doses of light, with a complete response at
36 Jcm2, despite a lower porphyrin level in tumour and
plasma. No cohesive pattern emerges in the values obtained
in patients treated with multiple fibres and it is not possible
at present from these measurements to deduce a general
fluence at which tumour response can be assured. Our data
suggests that satisfactory response rates occur with
2.0 mg kg-i PHP and with light doses in excess of 100 J cm-3
and that a complete response rate of 81% is achievable for
small tumours with doses greater than 500 J cm-3. Very large
tumours (60cm-3) can be completely lysed by the use of
multiple fibres appropriately placed within it. Clearly many
more measurements of energy fluence at critical points are
required before definitive conclusions can be drawn. We have
not yet shown whether non invasive measurements can be
used or how these relate to interstitial fluence values. Such
studies are necessary to advance light dosimetry and to allow
more scientific explanations of success or failure of clinical
PDT treatments. The aim of interstitial treatments and in
vivo measurements should be to ensure sufficient light reaches
the periphery of the tumour to ensure its successful eradica-
tion. Treatment times are long for the multiple fibre
treatments because of the need to keep the output power per
unit length of diffuser below levels known to induce hyper-
thermia and thus there is a need for efficient multiple beam1402 C.P. LOWDELL et al.
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Figure 2 The relationship between tumour volume (cm3) and total delivered light dose (Joules). Regression line fits to tumours
producing complete response (closed circles) and those lesions producing no change (open circles). No significant difference between
lines. P value>0.5.
Table V A comparison of the doses required to produce complete
responses (except where indicated: *partial response [PR]) in five
patients between superficial and interstitial PDT
Dose of PHP
Interstitial Superficial mgkg-'
1 250-1000 J cm-' 100 J cm-3 2.0
10/14 lesions treated 150 J cm-3
produced CR in this range
2 1400 J cm-3 100 J cm-3* 1.5
six lesions treated
at lower doses = N.C.
3 220Jcm-3 100Jcm-3 2.0
4 36OJCm-3* 225Jcm-3 1.5
5 70-210 Jcm-3 50 Jcm-3 2.0
Comparisons are intra-patient. Whilst a complete response (CR)
may be possible at lower doses than 100 Jcm-' in patient I with
superficial treatment, it would have been unlikely to occur at lower
doses than 250 J cm-I for interstitial PDT. In the cases ofpatient 3 a
light dose lower than 100 J cm-3, superficially delivered, produced a
PR, and patient 5, 50 Jcm-3 produced a PR in a thicker lesion.
Calculation of equivalent light doses is explained in the Materials
and methods section of the text.
splitters and for sufficient laser power. Although it is recog-
nised that there may be good reasons for combining PDT
and hyperthermia (Freitas, 1986; Levendag et al., 1988;
Mang & Dougherty, 1985). We have previously established
that the penetration depth of red light (630 nm) was 4 mm in
human breast cancer patients (Driver et al., 1991). In this
study we have occasionally noted necrosis at much greater
distances than would be predicted. In two patients skin nec-
rosis occurred at 16.5 and 8.75 mm from treatment fibres; an
experience reported by others (Barr et al., 1990). It has been
postulated that these distant effects may relate to prolonged
activation of long acting T lymphocytes and activation of
natural killer cells producing interleukins and tumour nec-
rosis factor.
Complete responses occurred at lower comparable light
doses for superficial than for interstitial PDT (Table V).
There are a number ofdifficulties when comparing superficial
PDT with interstitial PDT (McKenzie, 1985) and the figures
Table VI Energy fluence detected at the base of six treated
tumours, drug concentration and clinical outcome
Light dose
Given Energy fluence Drug conc. Clinical
Patient J Jcm-2 ng mg-' response
PT 200 130.2 2.52 CR Esc
PT 100 101.5 2.52 CR °Esc
PT 100 75.8 2.52 NC °Esc
PT 50 73.8 2.52 NC °Esc
NL 200 76.5 1.96 CR Esc
NL 50 35.5 1.96 CR °Esc
CR =Complete Response. NC =No Response. Esc = Eschar.
°Esc = No Eschar. The porphyrin concentration was obtained from
an untreated nodule and assumes that this is representative of the
porphyrin concentration in tumours of a similar morphology.
quoted do not take into account the distributional differences
between the two forms of treatment. Superficial therapy is
delivered to the tumour with a margin of normal tissue.
Interstitial therapy is centred within the tumour delivering
less light to the adjacent tumour supporting normal tissues,
especially the vasculature and thus exerts a lesser tumour bed
effect. The presence and significance of, a tumour bed effect
in PDT, is not proven. An increase in tumour response with
increasing field size, using superficial treatment in experi-
mental systems (Gilson et al., 1990) and shielding
experiments indicate that a certain amount of normal tissue
damage is necessary to obtain tumour control (Fingar &
Henderson, 1987). Incident light on the skin surface will fall
off exponentially in tissue, after up to 50% of the light has
been reflected (Parrish, 1983); so that light delivered
superficially is inhomogeneously distributed in tissue com-
pared to interstitial therapy, where all the delivered dose
should be, effectively, completely absorbed (i.e.: very little is
scattered out) by the tissues. Interstitial therapy is obviously
invasive and invevitably leads to blood surrounding the fibre.
Haemoglobin is likely to be a strong absorber oflight even at
this wavelength and may therefore reduce the amount of
light reaching the perimeter of the tumour. Hence a compen-
satory higher light dose is required to be isoequivalent.
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These factors may help explain the results seen clinically.
However the success of interstitial therapy gives hope that
this treatment may be applied curatively to a wider range of
malignancy with efficacy and safety (Ash & Brown, 1989). It
has been demonstrated that with care high complete response
rates are possible and that large volumes can be effectively
treated. Whether it is desirable to treat such large tumours
with PDT is debatable, it is rare that such tumours would
occur in the absence of metastatic disease, technically these
are laborious and time consuming procedures and as with
interstitial brachytherapy PDT is more likely to find a role in
the treatment of small volume disease. The clinical role for
interstitial PDT has still to be evaluated but photodynamic
therapy does have potential advantages over ionising radia-
tion and such a treatment may thus find as useful a place in
cancer treatment as interstitial radiotherapy and could be
extended to further anatomical sites.
We would like to acknowledge the support of the Yorkshire Cancer
Research Campaign who funded this work, and Dr David Vernon
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